

CITATION REPORT

List of articles citing

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

DOI: 10.2165/00003088-200544100-00005
Clinical Pharmacokinetics, 2005, 44, 1067-81.

Source: <https://exaly.com/paper-pdf/39421322/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
121	Single-dose clinical pharmacokinetic studies of gefitinib. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 1165-77	6.2	112
120	Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 633-44	6.2	54
119	Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions. 2006 , 36, 1013-80		24
118	CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. 2006 , 98, 1714-23		93
117	Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?. 2006 , 24, e60-1		19
116	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. 2007 , 13, 3731-7		237
115	Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients. 2007 , 20, 579-86		15
114	Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. 2007 , 13, 2684-91		83
113	Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. 2007 , 60, 661-70		15
112	Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. 2007 , 133, 169-76		13
111	Decreased biosynthesis of lung surfactant constituent phosphatidylcholine due to inhibition of choline transporter by gefitinib in lung alveolar cells. 2008 , 25, 417-27		19
110	Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. 2008 , 42, 1737-48		58
109	General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 669-80	6.2	73
108	Lifestyle habits as a contributor to anti-cancer treatment failure. 2008 , 44, 374-82		19
107	Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. 2008 , 36, 2355-70		110
106	Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. 2008 , 5, 268-78		77
105	Update on rifampin and rifabutin drug interactions. 2008 , 335, 126-36		103

104	Antifungal drugs. 2008 , 30, 316-335	1
103	Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives. 2009 , 23, 677-91	5
102	Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. 2009 , 68, 226-37	29
101	Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. 2009 , 69, 2303-28	39
100	Clinical pharmacokinetics of tyrosine kinase inhibitors. 2009 , 35, 692-706	316
99	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. 2009 , 20, 856-66	43
98	Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. 2010 , 125, 230-48	70
97	Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. 2010 , 128, 82-90	10
96	Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. 2010 , 38, 32-9	75
95	The Mycobacterium tuberculosis cytochrome P450 system. 2010 , 493, 82-95	68
94	Metabolism considerations for kinase inhibitors in cancer treatment. 2010 , 6, 1175-93	78
93	Gefitinib for the treatment of non-small-cell lung cancer. 2010 , 11, 1343-57	19
92	Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes. 2011 , 74, 103-11	11
91	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 371-403	6.2 80
90	Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams. 2011 , 3, 865-913	30
89	Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. 2011 , 11, 37-51	39
88	Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. 2011 , 29, e588-90	40
87	Clinically relevant drug interactions between anticancer drugs and psychotropic agents. 2011 , 20, 6-32	32

86	Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies. 2012 , 81, 58-74	3
85	Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans. 2011 , 5, 77-92	10
84	Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs. 2011 , 39, 1139-48	34
83	Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders. 2011 , 80, 466-75	31
82	Clinically-relevant anticancer-antidepressant drug interactions. 2012 , 8, 173-99	11
81	Sunitinib malate. 2012 , 37, 363-88	14
80	Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. 2012 , 29, 1960-76	71
79	Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. 2012 , 14, 94-101	24
78	Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry. 2012 , 61, 86-92	45
77	Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. 2013 , 71, 543-9	8
76	Pharmacokinetics, pharmacodynamics and toxicity of a combination of metoprolol succinate and telmisartan in Wistar albino rats: safety profiling. 2013 , 65, 68-78	11
75	Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. 2013 , 14, 502-7	40
74	Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. 2013 , 24, 731-5	5
73	Interactions between oral antineoplastic agents and concomitant medication: a systematic review. 2013 , 12, 403-20	16
72	Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data. 2013 , 8, e70330	61
71	A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib. 2014 , 36, 24-9	10
70	Drug interactions with solid tumour-targeted therapies. 2014 , 89, 179-96	68
69	Drug interactions with phytotherapeutics in oncology. 2014 , 10, 359-77	48

68	Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. <i>Journal of Pharmaceutical Sciences</i> , 2014 , 103, 3810-3833	3.9	25
67	Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. 2014 , 15, e315-26		156
66	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. 2014 , 40, 917-26		103
65	Selective inhibition of human solute carrier transporters by multikinase inhibitors. 2014 , 42, 1851-7		46
64	Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. 2014 , 34, 651-9		45
63	Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes. 2014 , 151, 210-7		30
62	[Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report]. 2014 , 69, 163-8		2
61	Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. 2015 , 55, 1012-23		56
60	Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. 2015 , 4, 354-60		6
59	Inhibition of SN-38 glucuronidation by gefitinib and its metabolite. 2015 , 75, 1253-60		10
58	Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. 2015 , 79, 241-53		81
57	Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. 2015 , 43, 490-509		91
56	Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. 2015 , 90, 307-13		16
55	Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction. 2015 , 76, 713-21		1
54	Gefitinib. 2016 , 518-520		
53	The Treatment of Coexisting Lung Cancer and Mycobacterium avium Complex Infection with Gefitinib, Rifabutin, Clarithromycin, and Ethambutol, Concomitant with the Measurement of the Blood Gefitinib Concentration: a Case Report. 2016 , 56, 355-360		0
52	Antifungal azoles [for systemic use]. 2016 , 584-601		
51	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. 2016 , 78, 941-947		5

50	Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. 2016 , 77, 48-53	19
49	Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer. 2017 , 23, 203-214	6
48	Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions. 2017 , 14, 1754-1759	13
47	Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. 2017 , 6, 517-523	12
46	Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy. 2017 , 35, 259-280	21
45	Analysis of the impact of lung cancer treatment on nontuberculous mycobacterial lung diseases. 2017 , 55, 45-50	10
44	Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro. 2017 , 11, 1283-1290	8
43	Alterations of Gefitinib Pharmacokinetics by Co-administration of Herbal Medications in Rats. 2018 , 24, 460-466	2
42	Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity. 2018 , 29, 471-476	3
41	Effects of Angelica gigas extract on the oral pharmacokinetics of gefitinib in rats. 2018 , 48, 295-300	2
40	Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. 2018 , 48, 1106-1112	8
39	Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole. 2018 , 58, 347-356	11
38	Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity. 2018 , 58, 263-268	10
37	Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. 2018 , 58, 485-493	9
36	Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. 2019 , 12, 5467-5484	22
35	CYP3A4/5 mediates the metabolic detoxification of humantenmine, a highly toxic alkaloid from Gelsemium elegans Benth. 2019 , 39, 1283-1292	9
34	Antidepressant-like effects of ginseng fruit saponin in myocardial infarction mice. 2019 , 115, 108900	8
33	Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. 2019 , 83, 849-858	7

32	Clinically relevant drug interactions with multikinase inhibitors: a review. 2019 , 11, 1758835918818347		40
31	Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development. 2020 , 13, 31-40		3
30	Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs. 2020 , 145, 102822		7
29	Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple quadrupole time-of-flight mass spectrometry. 2020 , 15, e0236523		6
28	Inhibition and induction of CYP enzymes in humans: an update. 2020 , 94, 3671-3722		41
27	Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML. 2020 , 2020, 4201727		2
26	Interferon-inducer antivirals: Potential candidates to combat COVID-19. 2021 , 91, 107245		17
25	Flavonoid-Mediated Modulation of CYP3A Enzyme and P-Glycoprotein Transporter: Potential Effects on Bioavailability and Disposition of Tyrosine Kinase Inhibitors.		0
24	Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers. 2021 , 10, 1044-1053		4
23	Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan. 2021 , 2, 217-224		0
22	Effect of Single-Dose and Short-Term Administration of Si Jun Zi Tang on the Pharmacokinetics of Gefitinib in Rats. 2021 , 2021, 6655449		
21	Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0104321	5.9	6
20	Tuberculosis treatment incompleteness in patients with lung cancer: occurrence and predictors. <i>International Journal of Infectious Diseases</i> , 2021 , 113, 200-206	10.5	0
19	The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study. <i>Journal of Pharmaceutical Sciences</i> , 2021 , 110, 3507-3519	3.9	1
18	Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor. <i>Cancer Management and Research</i> , 2021 , 13, 7517-7526	3.6	0
17	Toxicology, Safety and HerbDrug Interactions in Cancer Therapy. 2010 , 293-340		1
16	4. ???????. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2007 , 38, 23-28	0	1
15	ANTIFUNGAL DRUGS. 2010 , 647-775		

14	Safety Pharmacology: Similarities and Differences between Small Molecules and Novel Biopharmaceuticals. 1		
13	Impact of the Physiological Effects of Aging on the Pharmacokinetics and Pharmacodynamics of Systemic Lung Cancer Treatment. 2013 , 65-87		
12	Therapy options for advanced NSCLC. 2015 , 5-25		
11	Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018 , 9, 189-200	9.7	11
10	Effects of Astragaloside IV on the Pharmacokinetics of Metoprolol in Rats and Its Mechanism.. <i>Current Drug Metabolism</i> , 2022 ,	3.5	1
9	A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal Organoids.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
8	Rifampin drug-drug-interaction studies; reflections on the nitrosamine impurities issue.. <i>Clinical Pharmacology and Therapeutics</i> , 2022 ,	6.1	1
7	Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022 , 3, 100112	3	0
6	The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.		0
5	Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment. 2022 , 23, 14159		0
4	Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of DrugDrug Interaction and Improving Clinical Practice.		0
3	Activation/deactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy. DMD-MR-2022-001131		0
2	Drug-Drug Interaction Potential of SH-1028, a Third-generation EGFR-TKI: In Vitro and Clinical Trials.		0
1	Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges. 2023 , 9, 464		0